RAPPORT THERAPEUTICS INC
RAPPNASDAQTrading Snapshot
- Day Range
- $22.08 – $23.94
- 52-Week Range
- $23.75 – $52.93
- Volume (shares)
- 5,940,919
- Avg Volume (shares)
- —
- Shares Outstanding
- 48.0M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -8.9
- P/S Ratio
- 64.6x
- EPS (TTM)
- $-2.89
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +143.6%
RAPPORT THERAPEUTICS INC
RAPP
StockOtter · stockotter.spaceAbout RAPPORT THERAPEUTICS INC
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small m
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small m
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $64,443.60 in Stock
Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics NASDAQ: RAPP reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and supporting p
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
Why Is Rapport Therapeutics Stock Trading Higher Today?
Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro data.